Latest Breaking News On - Richa kumari - Page 3 : comparemela.com

Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update

/PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug.

Richa kumariJames levineMark erlanderKiki patelGilmartin groupExchange commissionPfizer global product developmentDana farber cancer institutePrnewswire cardiff oncology incCardiff oncology incMedicine team group lead for breast cancerTaft communicationsCardiff oncologyChief executive officerPfizer igniteVice president

Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

- Advance to first-line RAS-mutated mCRC follows the strong signal from new clinical and preclinical data, and agreement with FDA - - First-line mCRC represents substantial increase in patient.

Kiki patelMark erlanderJames levineAdam schayowitzFairooz kabbinavarRicha kumariMedicine team group lead for breast cancerGilmartin groupTaft communicationsPrnewswire cardiff oncology incCardiff oncology incExchange commissionPfizer incPfizer global product developmentPfizer igniteCardiff oncology

Irrigation department employee s son shot dead after entering his house in Patna, pistol magazine recovered from the spot

Irrigation department employee s son shot dead after entering his house in Patna, pistol magazine recovered from the spot
weeklyblitz.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from weeklyblitz.net Daily Mail and Mail on Sunday newspapers.

Kamleshwar prasad singhHazrat nizamuddinMeena deviNavish lakshmi narayanM lakshmi narayanSurendra singhAnkit kumarTadwa suithaRicha kumariIrrigation department in bihtaPunpun primary health centerIrrigation departmentSunil saoCircle inspector kamleshwar prasad singhParsa bazarPunpun primary health

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 24, 2023 /PRNewswire/ Cardiff Oncology, Inc. , a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies.

Kiki patelJames levineRicha kumariGilmartin groupPrnewswire cardiff oncology incCardiff oncology incTaft communicationsCardiff oncologyNasdaq listing ruleOncology contact

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug.

Richa kumariKiki patelJames levineGilmartin groupPrnewswire cardiff oncology incCardiff oncology incTaft communicationsCardiff oncologyNasdaq listing ruleOncology contact